Nuvation Bio Inc. (NUVB) stock
Close on Nov 11, 2026Market cap $1.51BP/E –Yield –
Nuvation Bio Inc. grew revenue 654.2% to $201.73M over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $1.51B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.51B
- P/E ratio
- –
- Price to sales
- 7.47
- Price to book
- 6.61
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $201.73M
- Net income
- -$135.93M
- EPS, diluted
- -$0.60
- Book value per share
- $647.91
- Diluted shares
- 0M
Trading
- Next earnings
- Mar 1, 2027 (estimated, during market hours)
- Previous close
- $4.20
- Open
- $4.27
- Day's range
- $4.22 – $4.38
- Volume
- 2,951,998
- Average volume (20 days)
- 5,108,315
- Index membership
- Russell 2000 (since Jun 2021), Russell 3000 (since Aug 2021)
- Beta (5 years)
- 1.46
- 52-week range
- $3.98 – $9.75
- RSI (14 days)
- 37.9
- Volatility (1 year)
- 82.4%
- Relative volume
- 0.53×
- WACC
- 12.2%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | NUVB | S&P 500 | Difference | NUVB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.2% | -2.4% | −11.8 pts | ||
| 3 months | -32.7% | -1.2% | −31.5 pts | ||
| Year to date | -52.1% | +12.3% | −64.4 pts | ||
| 1 year | -13.9% | +12.4% | −26.3 pts | ||
| 3 years | +232.6% | +78.8% | +153.7 pts | +49.3% | +21.4% |
| 5 years | -52.9% | +75.2% | −128.0 pts | -14.0% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Nuvation Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- Results
About Nuvation Bio
Pharmaceutical Preparations
Nuvation Bio Inc. is a biopharmaceutical company that develops and commercializes targeted therapies for cancer patients. The company operates within the oncology sector, discovering and advancing small-molecule treatments and drug-drug conjugates. Its lead commercial medicine is IBTROZI, an oral ROS1 inhibitor approved for adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer. Additionally, the company advances a clinical pipeline that includes safusidenib for patients with IDH1-mutant brain tumors, along with early-stage candidates designed through its drug-drug conjugate platform.
Company profile, executives and historyNuvation Bio stock: common questions
What is Nuvation Bio's stock price?
NUVB closed at $4.29 on Nov 11, 2026, up 2.14% on the day. Over the past 52 weeks it traded between $3.98 and $9.75.
What is Nuvation Bio's market cap?
Nuvation Bio was worth $1.51B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is NUVB's P/E ratio?
Nuvation Bio lost money over fiscal 2025 (diluted EPS -$0.60), so it has no meaningful P/E ratio.
How much revenue does Nuvation Bio make?
Nuvation Bio reported revenue of $201.73M for the twelve months to Sep 30, 2026, up 654.2% from a year earlier.
Does Nuvation Bio pay a dividend?
No. Nuvation Bio has not paid a cash dividend over the last twelve months.
When does Nuvation Bio report earnings next?
Nuvation Bio is expected to report Q4 FY2026 results on Mar 1, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has NUVB stock performed over the past year?
Including dividends, NUVB returned -13.9% over the past year, against +12.4% for the S&P 500.
How many NUVB shares are sold short?
62M shares were sold short at the latest FINRA report, 23.98% of the float, or 12.5 days of average trading volume.
Who are Nuvation Bio's competitors?
Companies most similar to Nuvation Bio by business, industry and size include PBYI, RCUS, HRTX, KURA, VSTM.
See a number that looks wrong?